Insulin glargine (Basaglar) vs SHR-3167

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

Insulin glargine (Basaglar)

Marketed by Eli Lilly and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT01421459 · Phase 3 · completed

The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)

Result source: NCT03338010

SHR-3167

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06688123 · Phase 2 · completed

The study randomized 275 adults with type 2 diabetes to once-weekly SHR-3167 (two titration schemes) or daily insulin glargine in an open-label, treat-to-target design. Its primary endpoint was change in HbA1c at week 20, a regulator-accepted measure in type 2 diabetes. Hengrui reports HbA1c reductions similar to glargine (differences -0.02% and -0.14%, with both confidence intervals crossing zero), but neither the registry nor the company states a non-inferiority margin, so whether the primary comparison was met cannot be called. The figures are company-reported and not peer reviewed.

Company release of an EASD 2026 late-breaking abstract; not peer reviewed and not posted on the registry.

Next expected readout: December 2026 · NCT07472725 (registry estimate)

Reported efficacy

Change from baseline to week 20 in HbA1c (HemoglobinA1c) (Week 0 to week 20.): Change in HbA1c from baseline to week 20 (primary): least-squares mean -1.37% (SHR-3167 group A, titration step 2 mg) and -1.49% (group B, titration step 1.5 mg) vs -1.35% with insulin glargine U100; differences -0.02% (95% CI -0.20 to 0.16) and -0.14% (95% CI -0.32 to 0.05); 275 randomized. No non-inferiority margin is stated.

Result source: NCT06688123

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin glargine (Basaglar)SHR-3167
HbA1c, change-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
—Trial running · NCT07913061
Body weight, change (kg)1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
—Trial running · NCT07913061
HbA1c below 7%43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010—Trial running · NCT07913061
Fasting plasma glucose, change—Not reported—Trial running · NCT07913061
3-point MACE (% with event)—Not reported—Trial running · NCT07913061

HbA1c, change

Insulin glargine (Basaglar)
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
SHR-3167
—Trial running · NCT07913061

Body weight, change (kg)

Insulin glargine (Basaglar)
1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
SHR-3167
—Trial running · NCT07913061

HbA1c below 7%

Insulin glargine (Basaglar)
43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010
SHR-3167
—Trial running · NCT07913061

Fasting plasma glucose, change

Insulin glargine (Basaglar)
—Not reported
SHR-3167
—Trial running · NCT07913061

3-point MACE (% with event)

Insulin glargine (Basaglar)
—Not reported
SHR-3167
—Trial running · NCT07913061
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

SHR-3167
Change in HbA1c from baseline to week 20 (primary): least-squares mean -1.37% (SHR-3167 group A, titration step 2 mg) and -1.49% (group B, titration step 1.5 mg) vs -1.35% with insulin glargine U100; differences -0.02% (95% CI -0.20 to 0.16) and -0.14% (95% CI -0.32 to 0.05); 275 randomized. No non-inferiority margin is stated. NCT06688123 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Insulin glargine (Basaglar): 4 of 4 rows · SHR-3167: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin glargine (Basaglar)
Dropout rate
11.9%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
7.6%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.4%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
1.6%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
0.4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT04153981 · Phase 4 · registry result, not featured evidence
Serious AEs
4%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 5.6%
upper respiratory tract infection 5.1%
abnormal weight gain 2.7%
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
nasopharyngitis 7.2%
upper respiratory tract infection 4%
weight increased 3.2%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
upper respiratory tract infection 20.3%
hypertension 5.6%
injection site pain 4.2%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin glargine (Basaglar)

HbA1c -1.286% (n=369) vs -1.338% (n=375) Lantus @ 24wk
absolute change · percentage points
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 9 more results
-0.452% (n=369) vs -0.481% (n=375) Lantus @ 4wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.871% (n=369) vs -0.866% (n=375) Lantus @ 8wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.134% (n=369) vs -1.143% (n=375) Lantus @ 12wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.265% (n=369) vs -1.321% (n=375) Lantus @ 16wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.294% (n=369) vs -1.379% (n=375) Lantus @ 20wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.336% (n=369) vs -1.438% (n=375) Lantus @ 24wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.25% (n=226) vs -1.22% (n=223) LANTUS® @ 24wk
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.27% (n=334) vs -1.23% (n=158) Lantus® @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.27% (n=334) vs -1.23% (n=158) Lantus® @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Weight 0.292 vs 0.526 Lantus kg @ 4wk
absolute change · kg
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 7 more results
0.999 vs 1.152 Lantus kg @ 8wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.271 vs 1.44 Lantus kg @ 12wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.55 vs 1.918 Lantus kg @ 16wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.734 vs 2.234 Lantus kg @ 20wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.914 vs 2.175 Lantus kg @ 24wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3 vs 1.7 LANTUS® kg @ 24wk
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.1 vs 1.2 Lantus® kg @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 43.7% (n=334) vs 44.9% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than or Equal to 6.5 23.4% (n=334) vs 16.5% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Weight -0.5 kg @ 24wk
absolute change · kg
No placebo or comparator arm
NCT04153981 · Phase 4 · registry result, not featured evidence
HbA1c -0.641% (n=259) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT04153981 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.86% (n=259) @ 24wk
NCT04153981 · Phase 4 · registry result, not featured evidence
SMBG 7-point Change mg/dL -38.7 mg @ 24wk
absolute change · mg
No placebo or comparator arm
Blood glucose concentration before breakfast
NCT04153981 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin glargine (Basaglar)'s landscape · SHR-3167's landscape